Drug Trial Radar · NCT07298343
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
356
Planned (sponsor's estimate)
Start
Jun 10, 2024
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Dr. Falk Pharma GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
Conditions
- Celiac Disease
Interventions
ZED1227 + SIGEDrug
oral treatment with different daily doses of ZED1227 vs placebo
PlaceboOther
Placebo + SIGE
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in CDSD GI Specific Symptom ScoreTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Center Mainz
Mainz, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.